Table 1 Comparison of no radiation, neoadjuvant radiation, and adjuvant radiation populations
From: Radiation therapy for retroperitoneal sarcoma: practice patterns in North America
Surgery only N = 5664(%)* | Adjuvant radiation N = 1091 (%)* | Neoadj uvant radiation N = 730 (%)* | p value | |
|---|---|---|---|---|
Patient characteristics | ||||
Age (Mean ± SD) | 62.43 (13.19) | 60.91 (12.59) | 60.65 (12.57) | < 0.001 |
Sex | < 0.001 | |||
Male | 2725 (48.1) | 473 (43.4) | 381 (52.2) | |
Female | 2939 (51.9) | 618 (56.7) | 349 (47.8) | |
Race | 0.022 | |||
Caucasian | 4826 (85.2) | 899 (82.4) | 621 (85.1) | |
Afican American | 505 (8.9) | 136 (12.5) | 67 (9.2) | |
Asian | 174 (3.1) | 37 (3.4) | 23 (3.2) | |
Other | 99 (1.8) | 10 (0.9) | 11 (15) | |
Unknown | 60 (1.1) | 9 (0.8) | 8 (1.1) | |
Ethnicity | < 0.001 | |||
No Hispanic | 4973 (87.8) | 952 (87.3) | 675 (92.5) | |
Hispanic | 450 (7.9) | 78 (7.2) | 33 (4.5) | |
Unknown | 241 (4.3) | 61 (5.6) | 22 (3.0) | |
Great Circle Distance (Median, IQR) | 17.6 (6.9, 52.1) | 11.7 (4.9, 28.2) | 28.4 (9.8, 83.6) | < 0.001 |
Primary Payor | < 0.001 | |||
Medicaid, Medicare, Other Government Insurance | 2742 (48.4) | 520 (47.7) | 333 (45.6) | |
Private Insurance | 2529 (44.7) | 530 (48.6) | 364 (49.9) | |
No Insurance | 173 (3.1) | 30 (2.8) | 22 (3.0) | |
Unknown | 220 (3.9) | 11 (10) | 11 (15) | |
Facility Location | < 0.001 | |||
New England/East Coast | 2291 (40.5) | 403 (36.9) | 364 (49.9) | |
Mid-West | 1327 (23.4) | 301 (27.6) | 173 (23.7) | |
South | 890 (15.7) | 139 (127) | 46 (6.3) | |
West Coast | 876 (15.5) | 192 (17.6) | 107 (14.7) | |
Unknown | 280 (4.9) | 56 (5.1) | 40 (5.5) | |
Facility Type | < 0.001 | |||
Academic/Research Pro gram | 3324 (58.7) | 452 (41.4) | 504 (69.0) | |
Community Cancer Program | 174 (3.1) | 76 (6.9) | 14 (1.9) | |
Comprehensive Community Cancer Program | 1314 (23.2) | 373 (34.2) | 106 (14.5) | |
Integrated Network Cancer Program | 572 (10.1) | 134 (12.3) | 66 (9.0) | |
Unknown | 280 (4.9) | 56 (5.1) | 40 (5.5) | |
Charlson-DeyoScore | 0.108 | |||
0 | 4329 (76.4) | 849 (77.8) | 574 (78.6) | |
1 | 958 (16.9) | 190 (174) | 120 (16.4) | |
2 | 266 (4.7) | 34 (3.1) | 21 (2.9) | |
≥3 | 111 (19) | 18 (17) | 15 (2.1) | |
Year of diagnosis | < 0.001 | |||
2004 | 268 (4.7) | 82 (7.5) | 21 (2.9) | |
2005 | 320 (5.7) | 76 (6.9) | 14 (1.9) | |
2006 | 320 (5.7) | 79 (7.2) | 33 (4.5) | |
2007 | 371 (6.6) | 99 (9.1) | 28 (3.8) | |
2008 | 384 (6.8) | 76 (6.9) | 33 (4.5) | |
2009 | 354 (6.3) | 88 (8.1) | 41 (5.6) | |
2010 | 361 (6.4) | 90 (8.3) | 51 (6.9) | |
2011 | 443 (7.8) | 91 (8.3) | 59 (8.1) | |
2012 | 430 (7.6) | 91 (8.3) | 52 (7.1) | |
2013 | 415 (7.3) | 82 (7.5) | 66 (9.0) | |
2014 | 477 (8.4) | 83 (7.6) | 66 (9.0) | |
2015 | 526 (9.3) | 56 (5.1) | 68 (9.3) | |
2016 | 500 (8.8) | 48 (4.4) | 87 (11.9) | |
2017 | 495 (8.7) | 50 (4.6) | 111 (152) | |
Annual hospital volume | < 0.001 | |||
Average < 5 cases per year | 4327 (76.4) | 1008 (92.4) | 498 (68.2) | |
Average 5–10 cases per year | 662 (11.7) | 74 (6.8) | 113 (155) | |
Average > 10 cases/year | 675 (11.9) | 9 (0.8) | 119 (163) | |
Tumor factors | ||||
Tumor differentiation | < 0.001 | |||
Well differentiated | 2010 (35.5) | 199 (18.2) | 166 (22.7) | |
Moderately differentiated | 731 (12.9) | 173 (15.9) | 92 (12.6) | |
Poorly differentiated | 1296 (22.9) | 350 (32.1) | 195 (26.7) | |
Undifferentiated | 865 (15.3) | 187 (17.1) | 140 (19.2) | |
Unknown | 762 (13.5) | 182 (167) | 137 (18.8) | |
Histology | < 0.001 | |||
Leiomyosarcoma | 1294 (22.9) | 398 (36.5) | 227 (31.1) | |
Liposarcoma | 3754 (66.3) | 534 (48.9) | 392 (53.7) | |
Other | 616 (10.9) | 159 (14.6) | 111 (15.2) | |
Tumor size | < 0.001 | |||
< 10 cm | 1143 (20.2) | 374 (34.3) | 133 (18.2) | |
> 10 cm | 3390 (59.9) | 600 (54.9) | 394 (53.9) | |
Unknown | 1131 (199) | 117 (107) | 203 (27.8) | |
Tumor grade | < 0.001 | |||
Grade 1 | 1186 (20.9) | 109 (9.9) | 118 (16.2) | |
Grade 2 | 642 (11.3) | 127 (116) | 100 (13.7) | |
Grade 3 | 1323 (23.4) | 314 (28.8) | 268 (36.7) | |
Unknown | 2513 (44.4) | 541 (49.6) | 244 (33.4) | |